Free Trial
Final Hours! MarketBeat All Access at $149 Until 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
C$6.50
+0.8%		C$6.50
C$4.52
▼
C$8.81
C$162.08MN/A19,376 shs19,980 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$3.95
-4.1%		$4.25
$1.07
▼
$11.46
$398.52M0.531.66 million shs779,006 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.00%0.00%0.00%0.00%0.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
-2.37%+6.74%+0.73%-12.71%-56.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
C$6.50
+0.8%		C$6.50
C$4.52
▼
C$8.81
C$162.08MN/A19,376 shs19,980 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$3.95
-4.1%		$4.25
$1.07
▼
$11.46
$398.52M0.531.66 million shs779,006 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.00%0.00%0.00%0.00%0.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
-2.37%+6.74%+0.73%-12.71%-56.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.00
N/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
2.71
Moderate Buy$11.22184.11% Upside

Current Analyst Ratings Breakdown

Latest RZLT and IPA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Outperform
10/13/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
10/6/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$9.00 ➝ $12.00
10/6/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform
10/6/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetMarket Outperform$11.00 ➝ $15.00
10/5/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeNeutral ➝ Overweight
9/30/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$9.00
9/29/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Buy$4.00 ➝ $7.00
9/25/2026
Rezolute, Inc. stock logo
RZLT
Rezolute
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy
(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
C$19.47M8.33C$0.77 per share8.39C$2.67 per share2.44
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/A-C$0.89N/AN/AN/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
-$77.59M-$0.76N/AN/AN/AN/A-62.99%-57.94%11/5/2026 (Estimated)

Latest RZLT and IPA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q1 2027
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.18N/AN/AN/A$1.12 millionN/A
9/24/2026Q4 2026
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.1479-$0.20-$0.0522-$0.20N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
1.70
5.06
4.29
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
9.68
9.68

Institutional Ownership

CompanyInstitutional Ownership
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%

Insider Ownership

CompanyInsider Ownership
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
14.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8024.94 millionN/ANot Optionable
Rezolute, Inc. stock logo
RZLT
Rezolute
5896.73 million82.43 millionOptionable

Recent News About These Companies

Rezolute (RZLT) Projected to Post Quarterly Earnings on Thursday
October 29 at 4:10 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-rezolute-rzlt-projected-to-post-quarterly-earnings-on-thursday-2026-10-29/
Rezolute (NASDAQ:RZLT) Stock Crosses Below Two Hundred Day Moving Average - Here's What Happened
October 27 at 4:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31161196
Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average - What's Next?
October 27 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-rezolute-nasdaq-rzlt-stock-price-crosses-below-200-day-moving-average-whats-next-2026-10-27/
Rezolute, Inc. (RZLT) Stock Price, News, Quote & History - Yahoo Finance
October 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RZLT/latest-news/
Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December
October 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rezolute-says-phase-3-uplift-205933177.html
Rezolute (NASDAQ:RZLT) Stock Rating Cut to Strong Sell at Zacks Research
October 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rezolute-nasdaq-rzlt-stock-rating-cut-to-strong-sell-at-zacks-research-2026-10-15/
Rezolute Completes Enrollment In Phase 3 UpLIFT Study Of Ersodetug For Tumor Hyperinsulinism
October 15, 2026  |  rttnews.comhttps://www.rttnews.com/3699113/rezolute-completes-enrollment-in-phase-3-uplift-study-of-ersodetug-for-tumor-hyperinsulinism.aspx
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3381134/0/en/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism.html
Rezolute, Inc. (RZLT) Latest Press Releases & Corporate News - Yahoo Finance
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RZLT/press-releases/
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
October 8, 2026  |  defenseworld.netD
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
October 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-rezolute-inc-nasdaq-rzlt-stock-now-rated-moderate-buy-by-sell-side-analysts-2026-10-08/
Cantor Fitzgerald upgrades Rezolute to overweight from neutral
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cantor-fitzgerald-upgrades-rezolute-to-overweight-from-neutral/ar-AA2dHoOU
Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/rezolute-upgraded-at-cantor-on-pre-bla-meeting-for-ersodetug/ar-AA2dHue3
Rezolute (NASDAQ:RZLT) Stock Price Target Raised at Citizens Jmp
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rezolute-nasdaq-rzlt-stock-price-target-raised-at-citizens-jmp-2026-10-06/
Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rezolute-says-fda-recommends-pre-120435720.html
Rezolute gets FDA nod for pre-BLA meeting despite phase 3 miss — retail expects huge rerating
October 5, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/rezolute-gets-fda-nod-for-pre-bla-meeting-despite-phase-3-miss-retail-expects-huge-rerating/ar-AA2dBtbf
Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-rezolute-nasdaq-rzlt-stock-sees-unusually-high-call-option-buying-2026-10-05/
Rezolute Prepares For Potential BLA Filing Of Ersodetug In Congenital HI
October 5, 2026  |  rttnews.comhttps://www.rttnews.com/3696465/rezolute-prepares-for-potential-bla-filing-of-ersodetug-in-congenital-hi.aspx
Rezolute receives FDA guidance for ersodetug pre-BLA meeting
October 5, 2026  |  grafa.comG
FDA Recommends Next Regulatory Step For Rezolute's Ersodetug;Stock Up
October 5, 2026  |  rttnews.comhttps://www.rttnews.com/3696473/fda-recommends-next-regulatory-step-for-rezolute-s-ersodetug-stock-up.aspx
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374399/0/en/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies CVE:IPA

C$6.50 +0.05 (+0.78%)
As of 11/25/2022

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$3.95 -0.17 (-4.13%)
Closing price 04:00 PM Eastern
Extended Trading
$3.96 +0.01 (+0.38%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas